p53 is functionally inhibited in clear cell renal cell carcinoma (ccRCC): a mechanistic and correlative investigation into genetic and molecular characteristics.
Biomarker
Renal cell carcinoma
The Cancer Genome Atlas
Tumor suppressor gene
p53
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
received:
17
05
2021
accepted:
28
08
2021
pubmed:
10
9
2021
medline:
6
11
2021
entrez:
9
9
2021
Statut:
ppublish
Résumé
Although p53 is rarely mutated in ccRCC, its overexpression has been linked to poor prognosis. The current study sought to elucidate the unique role of p53 in ccRCC with genomic, proteomic, and functional analyses. Data from the Cancer Genome Atlas (TCGA) were evaluated for genomic and proteomic characteristics of p53; a tissue micro array (TMA) study was carried out to evaluate the association of p53 and phosphorylated p53 (pp53) with clinical outcome. Mechanistic in vitro experiments were performed to confirm a pro-apoptotic loss of p53 in ccRCC and p53 isoforms as well as posttranslational modifications of p53 where assessed to provide possible reasons for a functional inhibition of p53 in ccRCC. A low somatic mutation rate of p53 could be confirmed. Although mRNA levels were correlated with poor prognosis and clinicopathological features, there was no monotonous association of mRNA levels with survival outcome. Higher p53 protein levels could be confirmed as poor prognostic features. In vitro, irradiation of ccRCC cell lines markedly induced levels of p53 and of activated (phosphorylated) p53. However, irradiated ccRCC cells demonstrated similar proliferation, migration, and p53 transcriptional activity like non-irradiated controls indicating a functional inhibition of p53. p53 isoforms and could not be correlated with clinical outcome of ccRCC patients. p53 is rarely mutated but the wildtype p53 is functionally inhibited in ccRCC. To investigate mechanisms that underlie functional inhibition of p53 may provide attractive therapeutic targets in ccRCC.
Identifiants
pubmed: 34499221
doi: 10.1007/s00432-021-03786-1
pii: 10.1007/s00432-021-03786-1
pmc: PMC8557161
doi:
Substances chimiques
TP53 protein, human
0
Tumor Suppressor Protein p53
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3565-3576Informations de copyright
© 2021. The Author(s).
Références
Horm Cancer. 2013 Feb;4(1):12-23
pubmed: 23011725
Cancers (Basel). 2018 Aug 25;10(9):
pubmed: 30149602
Cell Cycle. 2011 Nov 15;10(22):3920-8
pubmed: 22071692
Cell. 2018 Apr 5;173(2):400-416.e11
pubmed: 29625055
Nat Genet. 2018 Oct;50(10):1381-1387
pubmed: 30224644
J Urol. 2005 Mar;173(3):725-8
pubmed: 15711252
Nat Genet. 2013 Aug;45(8):849-50
pubmed: 23892664
BJU Int. 2012 Apr;109(8):1250-7
pubmed: 21756282
Clin Cancer Res. 2008 Aug 1;14(15):4726-34
pubmed: 18676741
Nat Med. 2017 Jul;23(7):869-877
pubmed: 28553932
Cancer Epidemiol Biomarkers Prev. 2009 Mar;18(3):894-900
pubmed: 19240241
J Biol Chem. 1999 Dec 10;274(50):35809-15
pubmed: 10585464
Cancer Cell. 2020 Dec 14;38(6):803-817.e4
pubmed: 33157048
J Cell Mol Med. 2004 Oct-Dec;8(4):423-31
pubmed: 15601571
Cell. 2017 Sep 7;170(6):1062-1078
pubmed: 28886379
Cancer. 2010 Feb 15;116(4):780-90
pubmed: 20052733
Nat Genet. 2013 Aug;45(8):860-7
pubmed: 23797736
EMBO Mol Med. 2013 Jun;5(6):949-64
pubmed: 23606570
Cell Death Differ. 2006 Jun;13(6):941-50
pubmed: 16601750
Proc Natl Acad Sci U S A. 2005 Nov 29;102(48):17448-53
pubmed: 16287968
J Pathol. 2015 Dec;237(4):460-71
pubmed: 26178300
Nat Commun. 2019 Dec 20;10(1):5800
pubmed: 31863007